YM443 in Subjects With Functional Dyspepsia

Exclusion Criteria

• •Significant renal, hepatic, bilirubin, cardiovascular, pulmonary, endocrine, metabolic, hematological, neurologic, or gastrointestinal (other than the one being studied) condition.
• •Subjects with diabetes mellitus are to be excluded.
• •Congenital or acquired long QT syndrome, or uncontrolled arrhythmias.
• •Prior surgery on the luminal GI tract.
• •History of any major psychiatric disorder, current depression or anxiety, alcohol abuse, or substance abuse in the last 2 years.
• •Any evidence or treatment for malignancy (with the exception of basal cell carcinoma) within the last 5 years.
• •Confirmed structural gastrointestinal disease.
• •Predominant symptoms of irritable bowel syndrome (IBS) (Rome II criteria) or gastroesophageal reflux disease (GERD) assessed at Visit 1 or 4.
• •Female subjects who are pregnant, lactating, or are likely to become pregnant during the study.
• •Males and females of child-bearing potential must be abstinent or agree to use contraceptive regimens throughout the study.
• •Any history or condition which, in the opinion of the Investigator, makes the subject unsuitable for any of the procedures used during this study or would not allow for safe completion of the study.
• •Known hypersensitivity to gastroprokinetics or proton pump inhibitors.
• •Use of anti-ulcer medications, antacid/acid suppression medications, gastroprokinetics, aspirin (\>325 mg daily), other NSAIDs, antibiotics, and other medications that effect the GI system within 2 weeks prior to Screening. Must be able to stay off these medications during the study, except for proton pump inhibitors (PPIs) administered during the PPI Run-in Period.
• •Required use of concomitant medications known to adversely interact with other gastroprokinetic agents or proton pump inhibitors.
• •H. pylori eradication therapy (PPIs, antibiotics, bismuth preparations) in the 2 weeks prior to the upper endoscopy.
• •Treatment for H. pylori required during the study.
• •Subject has received an investigational drug within 30 days or 10 half-lives, which ever is longer, or participated in more than 3 clinical studies within 12 months, prior to Visit 1.
• •Previous treatment with YM443.
• •Employees of the Yamanouchi Group or CROs involved in the study.
• •More than one subject per household to participate in the study.